Perinatal airway management in neonatal goiter: A healthcare cost and utilization project (HCUP) kids' inpatient database analysis.

INTRODUCTION: Fetal goiter is a rare congenital disorder that can present with life-threatening neonatal airway obstruction. Lifesaving and function-preserving airway management strategies are available, but routine delivery affords a limited window for intervention. Accordingly, fetal goiter is reported among the most common indications for ex-utero intrapartum treatment (EXIT). While EXIT prolongs the window for airway intervention to benefit the neonate, it elevates the risk to the pregnant person and requires extensive resources; therefore, data to guide ideal treatment selection are essential. This study aims to compare perinatal airway interventions between individuals with a birth hospitalization discharge diagnosis (BHDD) of goiter and the general population. MATERIALS AND METHODS: Individuals with and without BHDD of goiter were identified in the Healthcare Cost and Utilization Project (HCUP) Kids' Inpatient Database from 2000 to 2019. The frequency of airway interventions on day of life (DOL) 0 or 1 were compared using the Rao-Scott chi-square test. Additionally, gestational age, type of intervention, complications, mortality, birth weight, and length of stay were examined for the goiter cohort. RESULTS: Two-hundred eighty-seven weighted cases of goiter were identified in the study period. The population was 61 % male, 55 % White, and median birthweight was 3.3 kg. The median length of stay was 4.3 days, and average total charges were $42,332. Airway intervention on DOL 0 or 1 was performed in 16.9 % of individuals with goiter compared to 1.6 % in neonates without goiter (p < 0.001). Interventions in the goiter cohort included endotracheal intubation in 16 % of cases, laryngoscopy/bronchoscopy in 1-5% of cases, and tracheostomy in <1 % of cases. Fewer than 1 % of individuals undergoing intubation additionally had mass decompression/resection on DOL 0 or 1. No neonates received extracorporeal membrane oxygenation cannulation or cardiopulmonary resuscitation. Hypoxic encephalopathy occurred in <1 % of cases, among which endotracheal intubation was the only airway intervention performed. There were no mortalities among neonates with goiter. CONCLUSION: Individuals with BHDD of goiter receive significantly higher rates of perinatal airway intervention. In most cases, endoscopic interventions alone were sufficient to avoid hypoxic neurological complications. These findings contribute to data to aid in clinical counseling and empower patients to make informed decisions according to their values and treatment goals.

Goiter in a fresco by simone peterzano, master of caravaggio (1578-1582, Garegnano Charterhouse, Milan).

Simone Peterzano mostly known as the master of Caravaggio executed frescoes in the presbytery of Garegnano Charterhouse. One fresco details a shepherd with a goiter.

Thyroid Disease in Children and Adolescents.

The thyroid plays a major role in growth and development, and the hormones it produces can affect many different systems of the body. For this reason, the thyroid should always be at the front of our minds when evaluating children and adolescents. The symptoms of thyroid abnormalities can often be subtle and evolve over time, so we must have a high index of suspicion when providing care for our patients. It is important to understand what can go wrong with the thyroid, how to diagnose thyroid disease, and how to manage thyroid abnormalities. Whether it is structural changes in the thyroid such as goiter or nodules, functional changes that lead to hyperthyroidism or hypothyroidism, or thyroid cancer, a thorough examination and appropriate treatment is essential to maintain optimal cognitive and physical growth throughout childhood and adolescence. This article will discuss the most common thyroid abnormalities, how to diagnose them, and how to treat and manage them in both the short and long term. [Pediatr Ann. 2021;50(4):e143-e147.].

[Modern diagnosis and therapy of benign thyroid diseases]. / Moderne Abklärung und Therapie benigner Schilddrüsenerkrankungen.

Modern diagnosis and therapy of benign thyroid diseases Abstract. Benign thyroid diseases continue to be widespread endocrine disorders. Early recognition of their symptoms and exact diagnosis are the prerequisite of targeted therapy and minimal impairment of the patient's well-being. Drug treatment, radioiodine therapy, thermal ablation procedures and surgery have been shown to be successful treatment options. As guidelines for diagnosis and treatment of patients continue to evolve, an interdisciplinary approach ensures optimal diagnosis and management on every step in the care for these patients. We present three clinical scenarios for benign thyroid disease: the symptomatic goitre, the painful thyroid and the thyroid with hyperthyroidism.

Surgical management of benign thyroid disease in children.

Benign thyroid disease in children represents a wide spectrum of disease. While most benign thyroid disorders may be either monitored or managed medically, surgery is an important treatment, particularly for Graves' disease or large multinodular goiters. Multidisciplinary teams including specialists in pediatric endocrinology, genetics, radiology, pathology and surgery at high volume centers offer the safest and most effective management.

Stroke in Association with Thyroid Goitre: A Case Report.

Ischaemic stroke secondary to isolated internal carotid artery thrombus without risk factors is uncommon. A 55-year-old woman presented to the acute stroke unit with acute right middle cerebral artery territory infarction secondary to right internal carotid artery occlusion. There were no risk factors for cerebrovascular disease, but mediastinal imaging showed the presence of a large retrosternal goitre which was displacing the mediastinal structures including the brachiocephalic and common carotid artery. Intraluminal thrombus is visible in the displaced innominate artery and is the underlying cause for the stroke in our patient. This case highlights the importance of appropriate imaging of the mediastinum in cases with thyroid goitre.

[Thyroid medicine for ENT physicians]. / Schilddrüsenmedizin für HNO­Ärzte.

Diseases of the thyroid gland are frequent incidental findings during ultrasound examination of the neck. They affect nearly one third of the normal population. Treatment is not always indicated; however, laboratory diagnostic measures must be initiated to specify the disease. The primary indications for consulting a thyroid specialist are thyroid nodules, goiters, autonomy of the thyroid gland, autoimmune diseases, Graves' disease, and Hashimoto thyroiditis. The aim of this review is to provide an overview of the most important thyroid diseases and their treatment options.

How Should Thyroid-Related Quality of Life Be Assessed? Recalled Patient-Reported Outcomes Compared to Here-and-Now Measures.

BACKGROUND: The impact of thyroid disease on quality of life is an important disease aspect that is best investigated by patient-reported outcomes. Recent patient-reported outcomes research has raised concern about the validity of traditional retrospective questionnaires. Therefore, ecological momentary assessments of patients' subjective well-being have been introduced to avoid recall bias and improve contextual validity. Despite theoretical advantages, the measurement properties remain unsubstantiated. This study examines the relationship between the retrospective thyroid-related quality of life patient-reported outcome measure (ThyPRO) and a momentary (here-and-now) version of ThyPRO. METHODS: Eighty-three newly diagnosed hyperthyroid patients expected to undergo treatment completed questions on their thyroid-related quality of life. Head-to-head comparison was performed between 12 momentary items from four multi-item ThyPRO scales administered three times daily via a smartphone application during 28 days and the original retrospective ThyPRO on day 28. The measurement difference between recalled and momentary ratings was quantified for all four scales. Furthermore, correlations between the measures were investigated, and their agreement was explored using Bland-Altman plots. Finally, the study examined whether retrospective ratings were influenced by two forms of recall bias (the peak effect and the end effect). RESULTS: Retrospective and mean momentary ThyPRO ratings were highly correlated (Pearson's correlations: 0.74-0.88). However, retrospective ratings provided significantly higher scores (i.e., worse quality of life) on all scales. Bland-Altman plots showed a skewed distribution, indicating low levels of agreement. Results supported a peak effect for retrospective ratings on tiredness but not for the remaining scales. Further, results supported end effects for retrospective ratings of emotional susceptibility and anxiety. CONCLUSIONS: Retrospective and mean momentary ThyPRO ratings correlated strongly, but retrospective ratings were higher, indicating more disease impact. The differences were of magnitudes normally deemed clinically relevant. Limited evidence supported peak and end effect bias for retrospective assessments. The two measurement modalities did not appear congruent and thus cannot be used interchangeably. When designing clinical studies, whether to use a momentary or retrospective measurement method may depend on the aim of measurement. Further prospective analyses are needed to compare any beneficial effects, for example in terms of higher precision or sensitivity to clinical change, of momentary assessments.

Primer evento científico sobre enfermedades del tiroides realizado en Cuba / First scientific event on thyroid diseases carried out in Cuba

Introducción: el 28 de mayo de 1954, en los salones la Academia de Ciencias Médicas, Físicas y Naturales de La Habana, se organizó el Symposium sobre bocio y su tratamiento, primer evento científico sobre este tema endocrinológico realizado en Cuba. Objetivo: describir el contenido de las conferencias impartidas en el "Symposium sobre bocio y su tratamiento" realizado en 1954. Métodos: se utilizó el método histórico lógico, apoyado en la técnica de revisión documental. Resultados: el Symposium sobre bocio y su tratamiento, contó de cinco conferencias, las que fueron publicadas en los Anales de la Academia. Se hizo una valoración de los progresos en las últimas décadas en cuanto al diagnóstico, tratamiento y otros aspectos relacionados con las enfermedades del tiroides en Cuba. Conclusiones: este encuentro científico es el primero realizado en nuestro país sobre las enfermedades del tiroides, y evidencia el interés de un grupo de profesionales de la Medicina por divulgar los aspectos más actualizados sobre estos temas. Se destaca la figura del doctor Gonzalo E. Arostegui Aróstegui como uno de los profesionales más experimentados y conocedor de las enfermedades tiroideas en aquellos años(AU)

Introduction: the Symposium on goiter and its treatment was organized on May 28, 1954 in the halls of the Academy of Medical, Physical and Natural Sciences of Havana. It was the first scientific event on this endocrinological topic held in Cuba. Objective: to describe the content of the lectures given in the "Symposium on goiter and its treatment" carried out in 1954. Methods: the logical historical method was used, and it was supported by the documentary review technique. Results: the Symposium on goiter and its treatment had five lectures, which were published in the Annals of the Academy. An assessment of the progress made in the last decades in diagnosis, treatment and other aspects related to thyroid diseases in Cuba was carried out. Conclusions: this scientific meeting was the first held in our country on thyroid diseases, and showed the interest of a group of medical professionals to disseminate the most updated aspects on these topics. The figure of Dr. Gonzalo E. Arostegui Aróstegui stands out as one of the most experienced and knowledgeable professionals of thyroid diseases in those years(AU)

Primer evento científico sobre enfermedades del tiroides realizado en Cuba / First scientific event on thyroid diseases carried out in Cuba

Introducción: el 28 de mayo de 1954, en los salones la Academia de Ciencias Médicas, Físicas y Naturales de La Habana, se organizó el Symposium sobre bocio y su tratamiento, primer evento científico sobre este tema endocrinológico realizado en Cuba. Objetivo: describir el contenido de las conferencias impartidas en el "Symposium sobre bocio y su tratamiento" realizado en 1954. Métodos: se utilizó el método histórico lógico, apoyado en la técnica de revisión documental. Resultados: el Symposium sobre bocio y su tratamiento, contó de cinco conferencias, las que fueron publicadas en los Anales de la Academia. Se hizo una valoración de los progresos en las últimas décadas en cuanto al diagnóstico, tratamiento y otros aspectos relacionados con las enfermedades del tiroides en Cuba. Conclusiones: este encuentro científico es el primero realizado en nuestro país sobre las enfermedades del tiroides, y evidencia el interés de un grupo de profesionales de la Medicina por divulgar los aspectos más actualizados sobre estos temas. Se destaca la figura del doctor Gonzalo E. Arostegui Aróstegui como uno de los profesionales más experimentados y conocedor de las enfermedades tiroideas en aquellos años(AU)

Introduction: the Symposium on goiter and its treatment was organized on May 28, 1954 in the halls of the Academy of Medical, Physical and Natural Sciences of Havana. It was the first scientific event on this endocrinological topic held in Cuba. Objective: to describe the content of the lectures given in the "Symposium on goiter and its treatment" carried out in 1954. Methods: the logical historical method was used, and it was supported by the documentary review technique. Results: the Symposium on goiter and its treatment had five lectures, which were published in the Annals of the Academy. An assessment of the progress made in the last decades in diagnosis, treatment and other aspects related to thyroid diseases in Cuba was carried out. Conclusions: this scientific meeting was the first held in our country on thyroid diseases, and showed the interest of a group of medical professionals to disseminate the most updated aspects on these topics. The figure of Dr. Gonzalo E. Arostegui Aróstegui stands out as one of the most experienced and knowledgeable professionals of thyroid diseases in those years(AU)

Thyroid Disease Around the World.

Thyroid disease is one of the most common pathologies in the world, with two of the most clinically important subgroups being iodine deficiency and thyroid goiter, and thyroid cancer. This review looks at the current state of thyroid disease in the world and evaluates the future direction in terms of thyroid disease treatment and prevention. Several of the most impactful epidemiologic studies are presented and analyzed, as well as a brief overview of the current socioeconomic burden of disease.

Minimally invasive local ablative therapies in combination with radioiodine therapy in benign thyroid disease: preparation, feasibility and efficiency - preliminary results.

PURPOSE: Initial studies of combinations of radioiodine therapy (RIT) and local ablative procedures for the treatment of thyroid nodules have shown promising results. The goal of this study was to evaluate the effectiveness of RIT combined with radiofrequency ablation (RFA) in patients with goitres and to determine which ablative procedure is the most suitable for a combined therapy. METHODS: Thirty patients with goitres were divided into two subgroups. A test group of 15 patients received combined therapy (RIT + RFA) and a control group of 15 patients received RIT mono therapy. All patients underwent assessments including ultrasound, laboratory evaluation (T3, T4, TSH, TG, TPOAb, TgAbTRAb) and scintigraphic imaging with Tc-99m-Pertechnetate. The 3-month volume reduction was used to evaluate therapy effectiveness. RESULTS: Combined therapy (subgroup 1) resulted in a significant (p < 0.05) thyroid volume reduction (22.3 ± 54 ml/32.2 ± 58.2%) with better performance (p > 0.05) than the control group (20.2 ± 32.2 ml/29.6 ± 42.1%). All patients became euthyroid after treatment. No major discomfort or complications occurred. A review of the literature investigating combinations of other local ablative procedures with RIT was performed to determine the most promising combination. CONCLUSIONS: The present study confirms the positive experiences with the combined therapy of RIT and local ablative procedures shown in the current literature and approves this approach for the treatment of goitres with RFA + RIT. These findings, when confirmed by further studies, should expand the indication of combined therapy as a minimally invasive alternative to surgery.

[Iodine 131 joint radio frequency ablation treatment for child with hyperthyroidism goiter: one case report].

A 12-year-old girl presented with a history of cervical mass, and one week of throat discomfort and dyspnea. Five years ago, the patient was diagnosed as Hashimoto's thyroiditis and hyperthyroidism; she received antithyroid drug treatment, but the result was not satisfactory. B-ultrasonic showed that the size of thyroid gland was 8.1 cm×3.2 cm in the left and 8.2 cm×4.8 cm in the right. After iodine 131 combined with radiofrequency ablation (RFA) treatment, throat discomfort and recumbent breathing difficulties disappeared, and B-ultrasonic showed that the size of thyroid reduced to 2.3 cm×1.7 cm (left) and 2.8 cm×2.0 cm (right). No recurrence was observed during the two and a half years of follow-up.

Combination of Ultrasound-Guided Percutaneous Microwave Ablation and Radioiodine Therapy in Benign Thyroid Disease: A 3-Month Follow-Up Study.

PURPOSE: Pilot studies of combined therapies treating benign nodular goiters reported promising results. The aim of this study was to investigate the effectiveness of combined microwave ablation (MWA) and radioiodine therapy (RIT) with a special focus on thyroid function at the 3-month follow-up. MATERIALS AND METHODS: 15 patients (median age: 55 years) with a large goiter and benign thyroid nodules or Graves' disease were treated with the combined therapy. Serum levels of triiodothyronine (T3), thyroxine (T4), thyrotropin (TSH), thyroglobuline (Tg) and, additionally, antibody levels against thyroglobulin (TgAb), thyrotropin receptors (TRAb) and thyroid peroxidase (TPOAb) were measured at enrollment, post MWA and at the 3-month follow-up (3MFU). Furthermore, the goiter volume, I-131 dose and hospitalization time were analyzed to evaluate effectiveness. MWA was operated under local anesthesia with a system working in a wavelength field of 902 to 928 MHz. RESULTS: TSH, T4, T3 and Tg did not change at 3MFU, except for in two patients in whom the initial TSH levels improved to normal thyroid functioning levels at follow-up. One of the patients developed a high TRAb-level that receded back into the normal range. At 3MFU, the combined therapy showed a mean thyroid volume reduction of 26.4 ml ±â€Š7.9 ml (30.5 % ±â€Š4.6 % (p < 0.05)). By utilizing the combined therapy, administered activity could be reduced by 26.6 % ±â€Š4.8 % (p < 0.05) and hospitalization time by 30.9 % ±â€Š19.9 % (p < 0.05). CONCLUSION: The data confirmed the effectiveness of the combination of MWA with RIT. The combined therapy is an innovative and conservative approach and could become a safe alternative to surgery for the treatment of very large benign nodular goiters. Due to the short follow-up and the limited number of patients, further studies will be necessary. KEY POINTS: • The combined therapy shows a significant volume reduction in benign nodular goiters. • Initial MWA improves the RIT results by reducing the required therapy activity. • Thyroid function is preserved after combined therapy.

Antenatal diagnosis and treatment of hypothyroid fetal goiter in an euthyroid mother: a case report and review of literature.

Fetal goiter is an extremely rare complication of pregnancy. Its incidence is 1 in 40,000 deliveries. Antithyroid maternal therapy is responsible for 10-15% of fetal congenital hypothyroidism and can be considered as the most frequent underlying cause for this condition. The frequency of fetal goiter that is associated with fetal hypothyroidism and normal maternal thyroid function, as in our case, is even less frequent. Fetal goiter is associated with increased rate of perinatal complications and long-term morbidity, due to peripartum complications including labor dystocia due to its mass effect, as well as neonatal airway obstruction that may lead to hypoxic-ischemic brain injury and death. We present, in this study, a case report of late antenatal fetal goiter in an euthyroid woman and a literature review of the diagnosis and treatment of these cases.

The impact of goitre and its treatment on the trachea, airflow, oesophagus and swallowing function. A systematic review.

In this systematic review, we investigated the effects of goitre and its treatment on the trachea and the oesophagus. A total of 6355 papers were screened in scientific databases, which disclosed 40 original studies (nine descriptive and 31 interventional). Although most studies are hampered by a number of methodological shortcomings, it is uncontested that goitre affects the trachea as well as the oesophagus in a large proportion of people. This leads to upper airway obstruction, swallowing dysfunction, or both, which may remain undisclosed unless specifically investigated for. Assessment of the tracheal dimensions should be done by magnetic resonance imaging or computed tomography, and detection of upper airway obstruction by flow volume loops, with focus on the inspiratory component. A clinical evaluation of the oesophageal function is difficult to implement and could be replaced by available and validated questionnaires on swallowing. Although radioiodine therapy and thyroidectomy relieve the negative effect of goitre on the trachea and the oesophagus, many issues remain unexplored.

Assessing health-related quality of life in patients with benign non-toxic goitre.

Health-related quality of life (HRQoL) assessments are increasingly used to evaluate treatment effects and to shape the delivery of value based care. Valid generic and disease specific tools are available for quantifying HRQoL in patients with non-toxic goitre. However, few studies have applied these validated instruments to assess HRQoL in patients with benign non-toxic goitre. Limited evidence suggests that patients with non-toxic goitre have HRQoL impairments in multiple HRQoL domains. While the HRQoL-impact of non-toxic goitre may be small relative to other severely disabling medical conditions, treatment is almost exclusively elected for HRQoL indications. Thus better quantification of HRQoL, particularly at better (or more favorable) levels where many patients score, is essential. Web and mobile technologies have eased the ability to deliver surveys to patients. Routine consideration of HRQoL provides the opportunity to monitor the impact of treatment on the outcomes most meaningful for patients and the opportunity to help shape the delivery of value based health care.